Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Monoclonal"" wg kryterium: Temat


Tytuł :
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Autorzy :
Vernieri F; Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, Via Alvaro del Portillo, 200, 00128, Rome, Italy. .
Altamura C; Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, Via Alvaro del Portillo, 200, 00128, Rome, Italy.
Brunelli N; Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, Via Alvaro del Portillo, 200, 00128, Rome, Italy.
Costa CM; Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, Via Alvaro del Portillo, 200, 00128, Rome, Italy.
Aurilia C; Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy.
Egeo G; Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy.
Fofi L; Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy.
Favoni V; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Pierangeli G; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Lovati C; Headache Center, Neurology Unit, University Hospital L. Sacco, Milan, Italy.
Aguggia M; Neurology and Stroke Unit, Asti Hospital, Asti, Italy.
d'Onofrio F; Neurology Unit, San Giuseppe Moscati Hospital, Avellino, Italy.
Doretti A; Department of Neurology, Stroke Unit and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Milan, Italy.
Di Fiore P; Headache Center, Neurology and Stroke Unit, S. Carlo Borromeo Hospital, Milan, Italy.
Finocchi C; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Rao R; Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Bono F; Center for Headache and Intracranial Pressure Disorders, Neurology Unit, A.O.U. Mater Domini, Catanzaro, Italy.
Ranieri A; Headache Centre, Neurology and Stroke Unit, A. Cardarelli Hospital, Naples, Italy.
Albanese M; Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome, Italy.; Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Cevoli S; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Barbanti P; Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy.; San Raffaele University, Rome, Italy.
Pokaż więcej
Corporate Authors :
GARLIT Study Group
Źródło :
The journal of headache and pain [J Headache Pain] 2021 May 03; Vol. 22 (1), pp. 35. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Antibodies, Monoclonal*
Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Adult ; Antibodies, Monoclonal, Humanized ; Cohort Studies ; Double-Blind Method ; Female ; Humans ; Italy ; Male ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study.
Autorzy :
Zhao Y; Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
Cai L
Liu XY
Zhang H
Zhang JZ
Pokaż więcej
Źródło :
Chinese medical journal [Chin Med J (Engl)] 2021 May 04; Vol. 134 (11), pp. 1324-1328. Date of Electronic Publication: 2021 May 04.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal*/adverse effects
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized ; China ; Cohort Studies ; Humans ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Rituximab hypersensitivity reactions and tolerance of ofatumumab therapy.
Autorzy :
Ali SB; Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, and Department of Immunology, SA Pathology, Adelaide, Australia.
Yuson C; Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, Australia.
Hissaria P; Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, and Department of Immunology, SA Pathology, Adelaide, Australia. .
Pokaż więcej
Źródło :
Clinical and experimental rheumatology [Clin Exp Rheumatol] 2021 May-Jun; Vol. 39 (3), pp. 648-650. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized*
Antigens, CD20*
Animals ; Antibodies, Monoclonal/adverse effects ; Humans ; Mice ; Rituximab/adverse effects
Czasopismo naukowe
Tytuł :
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.
Autorzy :
Warren RB; Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.
Carrascosa JM; Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP), Autonomous University of Barcelona (UAB), Badalona, Spain.
Fumero E; Almirall R&D, Barcelona, Spain.
Schoenenberger A; Almirall R&D, Barcelona, Spain.
Lebwohl MG; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Szepietowski JC; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
Reich K; Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, Skinflammation® Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pokaż więcej
Źródło :
Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 Apr; Vol. 35 (4), pp. 919-927. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal*/therapeutic use
Psoriasis*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized ; Humans ; Recurrence ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
Autorzy :
Bodemer C; Department of Dermatology, Hôpital Necker-Enfants Malades, APHP, Paris, France.
Kaszuba A; DERMED Medical Services, Lodz, Poland.
Kingo K; Tartu University Hospital and University of Tartu, Tartu, Estonia.
Tsianakas A; Fachklinik Bad Bentheim, Bad Bentheim, Germany.
Morita A; Nagoya City University Hospital, Aichi, Japan.
Rivas E; Dermos, Guatemala City, Guatemala.
Papanastasiou P; Novartis Pharma AG, Basel, Switzerland.
Keefe D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Patekar M; Novartis Pharma AG, Basel, Switzerland.
Charef P; Novartis Pharma AG, Basel, Switzerland.
Zhang L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Cafoncelli S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Papavassilis C; Novartis Pharma AG, Basel, Switzerland.
Pokaż więcej
Źródło :
Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 Apr; Vol. 35 (4), pp. 938-947. Date of Electronic Publication: 2021 Jan 19.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal*/adverse effects
Psoriasis*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized ; Child ; Double-Blind Method ; Humans ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis.
Autorzy :
Yamaguchi Y; Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kanai Y; Medical Affairs, Kyowa Kirin Co., Ltd., Tokyo, Japan.
Kitabayashi H; Medical Affairs, Kyowa Kirin Co., Ltd., Tokyo, Japan.
Okada H; Clinical Sciences Research Laboratories, Translational Research Unit, R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan.
Nakagawa H; Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło :
The Journal of dermatology [J Dermatol] 2021 Mar; Vol. 48 (3), pp. 324-333. Date of Electronic Publication: 2020 Nov 08.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Antibodies, Monoclonal*
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized ; Humans ; Japan ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature.
Autorzy :
Liu LC; Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China.
Jin XH; Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China.
Sun C; Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China.
Xia JX; Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China.
Pokaż więcej
Źródło :
Dermatologic therapy [Dermatol Ther] 2021 Mar; Vol. 34 (2), pp. e14825. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antibodies, Monoclonal*/therapeutic use
Psoriasis*/diagnosis
Psoriasis*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized ; Female ; Humans ; Male ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action.
Autorzy :
Kast F; Department of Biochemistry, University of Zurich, Zurich, Switzerland.
Schwill M; Department of Biochemistry, University of Zurich, Zurich, Switzerland.; TOLREMO therapeutics AG, Muttenz, Switzerland.
Stüber JC; Department of Biochemistry, University of Zurich, Zurich, Switzerland.; Roche Innovation Center Munich, Penzberg, Germany.
Pfundstein S; Department of Biochemistry, University of Zurich, Zurich, Switzerland.; Zurich Integrative Rodent Physiology (ZIRP), University of Zurich, Zurich, Switzerland.
Nagy-Davidescu G; Department of Biochemistry, University of Zurich, Zurich, Switzerland.
Rodríguez JMM; Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Seehusen F; Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Richter CP; Department of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany.
Honegger A; Department of Biochemistry, University of Zurich, Zurich, Switzerland.
Hartmann KP; Department of Biochemistry, University of Zurich, Zurich, Switzerland.
Weber TG; Dynamic Biosensors GmbH, Planegg, Germany.
Kroener F; Dynamic Biosensors GmbH, Planegg, Germany.
Ernst P; Department of Biochemistry, University of Zurich, Zurich, Switzerland.; Dean's Office and Coordination Office of the Academic Medicine Zurich, University of Zurich, Zurich, Switzerland.
Piehler J; Department of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany.
Plückthun A; Department of Biochemistry, University of Zurich, Zurich, Switzerland. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Jun 18; Vol. 12 (1), pp. 3790. Date of Electronic Publication: 2021 Jun 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Breast Neoplasms/*therapy
Receptor, ErbB-2/*antagonists & inhibitors
Receptor, ErbB-2/*immunology
Animals ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Design ; Female ; HeLa Cells ; Humans ; Immunoglobulin G/immunology ; Immunotherapy/methods ; MCF-7 Cells ; Mice ; Mice, SCID ; Trastuzumab/therapeutic use ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials.
Autorzy :
Mazieres J; Institut Universitaire du Cancer de Toulouse, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France. Electronic address: .
Rittmeyer A; Department of Thoracic Oncology, Lungenfachklinik Immenhausen, Immenhausen, Germany.
Gadgeel S; Henry Ford Cancer Institute, Henry Ford Hospital, Detroit, Michigan.
Hida T; Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Gandara DR; Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California.
Cortinovis DL; SC Oncologia Medica, SS Lung Unit Asst Ospedale San Gerardo, Monza, Italy.
Barlesi F; CNRS, INSERM, CRCM, APHM, Aix-Marseille University, Marseille, France.
Yu W; US Medical Affairs, Genentech, Inc., South San Francisco, California.
Matheny C; Product Development, Oncology, Genentech, Inc., South San Francisco, California.
Ballinger M; Product Development, Oncology, Genentech, Inc., South San Francisco, California.
Park K; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Jan; Vol. 16 (1), pp. 140-150. Date of Electronic Publication: 2020 Nov 06.
Typ publikacji :
Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal*
Docetaxel*
Lung Neoplasms*/drug therapy
Antibodies, Monoclonal, Humanized ; Humans
Czasopismo naukowe
Tytuł :
Ocular surface disease associated with dupilumab treatment for atopic diseases.
Autorzy :
Utine CA; Department of Ophthalmology, Dokuz Eylul University, Izmir, Turkey; Izmir Biomedicine and Genome Center, Izmir, Turkey.
Li G; The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Asbell P; The Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN, USA.
Pflugfelder S; Department of Ophthalmology, Baylor College of Medicine, Houston, TX, USA.
Akpek E; The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: .
Pokaż więcej
Źródło :
The ocular surface [Ocul Surf] 2021 Jan; Vol. 19, pp. 151-156. Date of Electronic Publication: 2020 May 18.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Monoclonal, Humanized*
Dermatitis, Atopic*/drug therapy
Antibodies, Monoclonal ; Humans ; Interleukin-13
Czasopismo naukowe
Tytuł :
Complete skin clearance and beyond.
Autorzy :
Schmitt-Egenolf M; Department of Public Health and Clinical Medicine, Dermatology, Umeå University, Umeå, SE-901 87, Sweden.; Centre for Pharmacoepidemiology, Karolinska Institutet, SE-171 77, Stockholm, Sweden.
Pokaż więcej
Źródło :
The British journal of dermatology [Br J Dermatol] 2021 Jan; Vol. 184 (1), pp. 3-4. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Antibodies, Monoclonal, Humanized*
Psoriasis*
Antibodies, Monoclonal ; Humans ; Skin
Czasopismo naukowe
Tytuł :
Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy.
Autorzy :
Kramer K; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. .
Donzelli MA; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Pessin MS; Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Aug; Vol. 70 (8), pp. 2411-2414. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
B7 Antigens/*metabolism
Cell Proliferation/*drug effects
Cerebrospinal Fluid/*drug effects
Mast Cells/*drug effects
Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Cell Proliferation/radiation effects ; Cerebrospinal Fluid/radiation effects ; Child ; Humans ; Immunotherapy/methods ; Iodine Radioisotopes/therapeutic use ; Male ; Mast Cells/radiation effects ; Neuroblastoma/radiotherapy ; Neuroblastoma/therapy ; Radioimmunotherapy/methods
Czasopismo naukowe
Tytuł :
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Autorzy :
Howard JF Jr; Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: .
Bril V; Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, ON, Canada.
Vu T; Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Karam C; Penn Neuroscience Center-Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Peric S; Neurology Clinic, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Margania T; Department of Neurology and Neurorehabilitation, New Hospitals, Tbilisi, Georgia.
Murai H; Department of Neurology, School of Medicine, International University of Health and Welfare, Narita, Japan.
Bilinska M; Department and Clinic of Neurology, Wroclaw Medical University, Wroclaw, Poland.
Shakarishvili R; Sarajishvili Institute of Neurology and Neurosurgery, Tbilisi, Georgia.
Smilowski M; Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland.
Guglietta A; argenx, Ghent, Belgium.
Ulrichts P; argenx, Ghent, Belgium.
Vangeneugden T; argenx, Ghent, Belgium.
Utsugisawa K; Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
Verschuuren J; Department of Neurology, Leiden University Medical Center, Leiden, Netherlands.
Mantegazza R; Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
Pokaż więcej
Corporate Authors :
ADAPT Investigator Study Group
Źródło :
The Lancet. Neurology [Lancet Neurol] 2021 Jul; Vol. 20 (7), pp. 526-536.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Immunoglobulin Fc Fragments/*therapeutic use
Myasthenia Gravis/*drug therapy
Activities of Daily Living ; Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Autoantibodies/immunology ; Double-Blind Method ; Female ; Headache/drug therapy ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Myasthenia Gravis/immunology ; Receptors, Cholinergic/immunology
Czasopismo naukowe
Tytuł :
2021 American Thoracic Society International Conference.
Autorzy :
Venkatesan P
Pokaż więcej
Źródło :
The Lancet. Respiratory medicine [Lancet Respir Med] 2021 Jul; Vol. 9 (7), pp. e65-e66. Date of Electronic Publication: 2021 Jun 01.
Typ publikacji :
Wiadomości
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Asthma/*drug therapy
Bronchodilator Agents/*therapeutic use
COVID-19/*drug therapy
Receptors, Glucocorticoid/*antagonists & inhibitors
Albuterol/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Budesonide/therapeutic use ; Child ; Drug Therapy, Combination ; Humans ; SARS-CoV-2 ; Societies ; United States
Periodyk
Tytuł :
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.
Autorzy :
Focosi D; North-Western Tuscany Blood Bank, Pisa University Hospital, Via Paraisa 2, 56124 Pisa, Italy.
Tuccori M; Division of Pharmacovigilance, Pisa University Hospital, Via Paradisa 2, 56124 Pisa, Italy.
Baj A; Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy.
Maggi F; Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy.
Pokaż więcej
Źródło :
Viruses [Viruses] 2021 Jun 23; Vol. 13 (7). Date of Electronic Publication: 2021 Jun 23.
Typ publikacji :
Editorial
MeSH Terms :
Antibodies, Monoclonal/*immunology
Antibodies, Viral/*blood
Plasma/*immunology
SARS-CoV-2/*immunology
Viral Vaccines/*immunology
Antibodies, Monoclonal, Humanized/immunology ; Antibodies, Neutralizing/immunology ; COVID-19/therapy ; Humans ; Immunization, Passive/standards ; In Vitro Techniques ; Neutralization Tests ; Spike Glycoprotein, Coronavirus/immunology
SCR Protocol :
COVID-19 serotherapy
Opinia redakcyjna
Tytuł :
Neutralizing monoclonal antibodies for treatment of COVID-19.
Autorzy :
Taylor PC; Botnar Research Centre, University of Oxford, Oxford, UK. .
Adams AC; Eli Lilly and Company, Indianapolis, IN, USA.
Hufford MM; Eli Lilly and Company, Indianapolis, IN, USA.
de la Torre I; Eli Lilly and Company, Indianapolis, IN, USA.
Winthrop K; Oregon Health & Science University, Portland, OR, USA.
Gottlieb RL; Baylor University Medical Center, Dallas, TX, USA.; Baylor Scott & White Research Institute, Dallas, TX, USA.
Pokaż więcej
Źródło :
Nature reviews. Immunology [Nat Rev Immunol] 2021 Jun; Vol. 21 (6), pp. 382-393. Date of Electronic Publication: 2021 Apr 19.
Typ publikacji :
Journal Article; Review
MeSH Terms :
SARS-CoV-2*/drug effects
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Antibodies, Monoclonal/*therapeutic use
Antibodies, Neutralizing/*therapeutic use
Antibodies, Viral/*therapeutic use
COVID-19/*therapy
Antibodies, Monoclonal, Humanized/therapeutic use ; Antibody-Dependent Enhancement ; COVID-19/immunology ; COVID-19/virology ; Drug Development ; Drug Resistance, Viral/genetics ; Drug Resistance, Viral/immunology ; Humans ; Immunization, Passive/adverse effects ; Immunization, Passive/methods ; Models, Immunological ; Pandemics
SCR Protocol :
COVID-19 serotherapy
Czasopismo naukowe
Tytuł :
Interstitial nephritis with pembrolizumab: A case report and review.
Autorzy :
Peláez Bejarano A; Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón Jiménez, Huelva, Spain.
Montero Pérez O; Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón Jiménez, Huelva, Spain.
Inoriza Rueda A; Unidad de Gestión Clínica Oncología Médica, Hospital Juan Ramón Jiménez, Huelva, Spain.
Garrido Martínez MT; Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón Jiménez, Huelva, Spain.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Jun; Vol. 27 (4), pp. 1046-1051. Date of Electronic Publication: 2020 Oct 12.
Typ publikacji :
Case Reports; Journal Article; Review
MeSH Terms :
Antibodies, Monoclonal, Humanized/*adverse effects
Nephritis, Interstitial/*chemically induced
Nephritis, Interstitial/*diagnostic imaging
Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Humans ; Lung Neoplasms/blood ; Lung Neoplasms/drug therapy ; Male ; Middle Aged ; Nephritis, Interstitial/blood
Czasopismo naukowe
Tytuł :
Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1).
Autorzy :
Papp K; Probity Medical Research and K Papp Clinical Research, Waterloo, ON, Canada.
Menter A; Baylor Scott & White, Dallas, TX, USA.
Leonardi C; Central Dermatology, St. Louis, MO, USA.
Soung J; Southern California Dermatology, Santa Ana, CA, USA.
Weiss S; Direct Dermatology, Palo Alto, CA, USA.
Pillai R; Bausch Health US, LLC, Petaluma, CA, USA.
Jacobson A; Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ, USA.
Pokaż więcej
Źródło :
The British journal of dermatology [Br J Dermatol] 2020 Dec; Vol. 183 (6), pp. 1037-1048. Date of Electronic Publication: 2020 Jul 05.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal*/adverse effects
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized ; Double-Blind Method ; Humans ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis.
Autorzy :
Van den Berghe N; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: .
Truffot A; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: .
Peeters M; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: .
Compernolle G; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: .
Brouwers E; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: .
Soenen R; Department of Dermatology, Ghent University Hospital, Ghent, Belgium. Electronic address: .
Grine L; Department of Dermatology, Ghent University Hospital, Ghent, Belgium. Electronic address: .
Gils A; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: .
Imbrechts M; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: .
Pokaż więcej
Źródło :
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2020 Sep 10; Vol. 189, pp. 113433. Date of Electronic Publication: 2020 Jun 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized*
Psoriasis*/drug therapy
Antibodies, Monoclonal ; Humans ; Immunoassay
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies